Work

Clinical outcomes of patients with metastatic fumarate hydratase‐deficient renal cell carcinoma: A single‐center case series

Year: 2025
Type: article
Study design: Observational Study
Abstract: Among non-clear cell renal cell carcinoma (nccRCC), fumarate hydratase-deficient renal cell carcinoma (FHdRCC) is a new entity that appeared in the World Health Organization (WHO) classification in 2022. 1 The genetic form of FHdRCC is the hereditary leiomyomatosis and renal cell carcinoma (RCC), which is an inherited syndrome that causes multiple cutaneous leiomyomas, uterine leiomyomas, and nccRCC. 2 Although FHdRCC is a rare, aggressive subtype of RCC, 2,3 the treatment effectiveness and outcomes of modern therapies including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor (ICI) are poorly understood.Recently, FHdRCC has been shown to represent negative staining of fumarate hydratase (FH) and positive staining of 2-succinate cysteine (2-SC).4 In this study, we attempted to elucidate the treatment effectiveness and outcomes of modern therapies in patients with FHdRCC.This retrospective study included 35 patients with metastatic nccRCC pathologically diagnosed between April 2008 and March 2023.Immunostainings for FH (clone: J-13, cat.no.: sc-100743; Santa Cruz Biotechnology, USA) and 2-SC (cat.no.: crb2005017e; Discovery, UK) were performed to confirm the diagnosis of FHdRCC.Clinical variables included in this study were age, sex, Karnofsky performance status, clinical symptoms, metastatic sites, and the International Metastatic RCC Database Consortium (IMDC) risk categories.Response to systemic therapy was objectively evaluated by CT scan every 2 or 3 months using the Response Evaluation Criteria in Solid Tumors guideline, version 1.1.5 The swimmer and waterfall plots were drawn using EZR, version 1.62.Among 35 patients with metastatic nccRCC, 10 patients (29%) were pathologically diagnosed with FHdRCC (Figure 1a).Three (30%) patients were primarily diagnosed with FHdRCC after the WHO classification was revised, whereas seven (70%) patients had initially been classified into different categories [papillary renal cell carcinoma (pRCC): 4/9 (44%) and collecting duct carcinoma (CDC): 3/5 (60%)] before revision.The median patient age was 45 years (range: 24-73 years), and eight (80%) patients were male.The IMDC risk categories were favorable, intermediate, and poor in three (30%), six (60%), and one (10%) patients, respectively.A comprehensive genomic profiling test using tumor samples was performed in four cases after immunohistochemical analysis, and germline testing in three, identifying pathogenic FH variants in all.Genetic counseling was subsequently provided.First-line regimens given were nivolumab + ipilimumab, nivolumab + cabozantinib, and single-agent TKI in three (30%), four (40%), and three (30%) patients, respectively.Among six patients who received first-line nivolumab-based therapy, five (83%) patients were still on first-line treatment, whereas one (17%) patient discontinued first-line treatment due to an immune-related adverse event.Three (30%) and one (10%) patients received later-line TKIs and nivolumab, respectively.The overall response rates of first-line therapies were 100%, 75%, and 33% in nivolumab + ipilimumab, nivolumab + cabozantinib, and single-agent TKI, respectively (Figure 1b).Median tumor shrinkage rates of first-line therapies were 90%, 59%, and 13% in nivolumab + ipilimumab, nivolumab + cabozantinib, and single-agent TKI, respectively (Figure 1c).To date, the mean and median observation periods were 12.6 months and 17.3 months, respectively.One-, two-, and three-year overall survival (OS) rates were 100%, 83%, and 63%, respectively.FHdRCC has notable characteristics.First, FHdRCC is an aggressive subtype of RCC with a poor prognosis.3,6 However, a recent retrospective, multicenter analysis demonstrated favorable outcomes of ICI + TKI compared with single-agent TKI.6 The median OS of patients treated with first-line ICI + TKI and single-agent TKI was not reached and 18.0 months, respectively.In our single-center cohort of 10 patients with metastatic FHdRCC, first-line ICI-based therapy showed a trend toward better tumor shrinkage than single-agent TKI.Second, FHdRCC with a pathogenic germline FH variant is common, and as a result, such
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4406936070
FWCI: 0.369
Cites: 7
Cited by: 1
Related to: 10